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Abstract
Chitosan is a cationic polymer of natural origin and has been widely explored as a pharmaceutical excipient for a broad
range of biomedical applications. While generally considered safe and biocompatible, chitosan has the ability to induce
inflammatory reactions, which varies with the physical and chemical properties. We hypothesized that the previously
reported zwitterionic chitosan (ZWC) derivative had relatively low pro-inflammatory potential because of the aqueous
solubility and reduced amine content. To test this, we compared various chitosans with different aqueous solubilities or
primary amine contents with respect to the intraperitoneal (IP) biocompatibility and the propensity to induce pro-
inflammatory cytokine production from macrophages. ZWC was relatively well tolerated in ICR mice after IP administration
and had no pro-inflammatory effect on naı¨ve macrophages. Comparison with other chitosans indicates that these
properties are mainly due to the aqueous solubility at neutral pH and relatively low molecular weight of ZWC. Interestingly,
ZWC had a unique ability to suppress cytokine/chemokine production in macrophages challenged with lipopolysaccharide
(LPS). This effect is likely due to the strong affinity of ZWC to LPS, which inactivates the pro-inflammatory function of LPS,
and appears to be related to the reduced amine content. Our finding warrants further investigation of ZWC as a functional
biomaterial.
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Introduction
Chitosan is a linear copolymer of D-glucosamine (2-amino-2-
deoxy-D-glucose) and N-acetyl-D-glucosamine (2-acetamido-2-
deoxy-D-glucose), obtained by partial (usually.80%) deacetyla-
tion of chitin, the main component of exoskeletons of insects and
crustaceans [1]. Chitosan has low oral toxicity (oral LD50:
.10,000 mg/kg in mouse and .1500 mg/kg in rats [2,3]) and
has been used in dietary supplements. It is also known to be safe
for topical use and as an ingredient of medical devices or cosmetics
[2,4,5]. Therefore, chitosan is considered a safe and biocompatible
material, and has been widely explored as a pharmaceutical
excipient for a variety of applications such as wound healing [6,7],
surgical adhesives [8,9], mucoadhesive oral drug/gene delivery
[10,11], gene delivery [12,13], and tissue engineering [2,14–16].
With a pKa of ,6.5, chitosan is insoluble in water at neutral
pH, where the majority of amines are deprotonated, but it is
positively charged and water-soluble at acidic pH [11]. The
limited solubility of chitosan in neutral pH provides a unique
opportunity to form nanoparticulate drug/gene delivery platforms
[11], but it is also an obstacle if one intends to apply chitosan as a
solution in the physiological condition [13]. To improve chitosan
solubility in a broader range of pH, the amine groups of chitosan
are partially quaternized [13] or conjugated with a sugar moiety
[17]. Glycol chitosan, a chitosan derivative with 2-hydroxyethy-
lether groups in the 6-O position, is also used when aqueous
solubility of chitosan at neutral pH is desired [18–21]. We have
recently reported that chitosan partially amidated with succinic
anhydride has a unique pH-dependent charge profile, with
isoelectric points (pI) tunable from pH 5 to 7 [22]. The chitosan
derivative, which we call zwitterionic chitosan (ZWC), is soluble in
water at pH’s below and above the pI according to the change of
its net charge.
Due to the unique pH dependence and aqueous solubility, we
propose to use ZWC for parenteral applications, specifically as a
component of nanoparticulate drug delivery systems. For nano-
particles or the components to be compatible with parenteral
applications, they should not activate immune cells in the
bloodstream (monocytes, platelets, leukocytes, and dendritic cells)
and in tissues (resident phagocytes), which would cause premature
removal of the nanoparticles and/or elicit inflammatory responses
[23]. There are split opinions about biocompatibility of chitosan.
Some studies indicate that chitosan has various biological activities
that can adversely influence its parenteral applications. Chitosan is
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shown to cause hemostatic effect and complement activation
[2,24–26]. Studies also show that chitosan is an inducer of pro-
inflammatory cytokines or chemokines [2,16,27–32]. Intraperito-
neal (IP) administration of chitosan induces a large number of
macrophages with hyperplasia in the mesenterium of mice [33]
and causes severe peritoneal adhesions in rabbits [27]. On the
other hand, others do not observe pro-inflammatory activities of
chitosans [34–36]. Some studies with chitosan derivatives and
chitosan oligosaccharides even find that the chitosans have a
protective effect on various cells and prevent cytokine induction
[37–41]. These studies suggest that the biocompatibility of
chitosans may not be generally assumed but varies with the
physical and chemical properties of chitosans.
In our previous study, ZWC showed excellent compatibility
with blood components and was well tolerated upon IP injection
[22]. Compared to its precursor, low molecular weight chitosan
(LMCS), the ZWC showed lower potential to cause hemolysis,
complement activation, and inflammatory responses [22]. To
understand what makes ZWC relatively more compatible with IP
application, here we compare ZWC with other chitosans having
different aqueous solubilities, primary amine contents, or molec-
ular weights (summarized in Table S1), with respect to the tissue
reactions to IP-administered chitosans and the propensity to
induce pro-inflammatory cytokine production from macrophages.
We report that ZWC is not only distinguished from the other
chitosans in IP biocompatibility but also possesses a unique ability
to suppress pro-inflammatory responses of activated macrophages.
These properties are attributable to good aqueous solubility,




Mouse peritoneal macropahge cell lines were purchased from
ATCC (CRL-2457). All media and their components were
purchased from Invitrogen (Carlsbad, CA). All other reagents
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Chitosan glutamate (Protasan UP G113; MW: 200 kDa; degree of
deacetylation: 75–90%) was purchased from Novamatrix (Nor-
way), low-molecular-weight chitosan (LMCS; MW: 15 kDa;
degree of deacetylation: 87%) from Polysciences, and glycol
chitosan (MW: 82 kDa; degree of deacetylation: 83%) from Wako
USA (Richmond, VA).
Synthesis of ZWC and other chitosans
ZWC was synthesized as previously described [22]. Briefly,
LMCS was first dissolved in 1% acetic acid to obtain an acetate
salt form. LMCS acetate 200 mg was dissolved in 30 mL of
deionized water. Succinic anhydride was added as solid to the
LMCS solution under vigorous stirring varying the quantities
according to the desired molar feed ratio of anhydride to amine
(An/Am ratio). The pH of the reaction mixture was maintained at
6–6.5 and subsequently increased to 8–9 with 1 N NaHCO3. After
an overnight reaction at room temperature under stirring, the
reaction mixture was dialyzed against water (molecular weight
cutoff: 3500) maintaining the pH at 8–9 with 1 N NaOH. The
purified ZWC was freeze-dried and stored at 220uC. Unless
specified otherwise, ZWC prepared with An/Am ratio of 0.7 was
used in most experiments.
Ethics statement
Animals were cared for in compliance with a protocol
specifically approved for this study by the Purdue Animal Care
and Usage Committee (Approval number: 09-093-11), in
conformity with the NIH guidelines for the care and use of
laboratory animals.
In vivo biocompatibility
Chitosan glutamate, glycol chitosan, and ZWC were tested for
tissue responses following IP administration (800 mg/kg). Chit-
osan and buffer controls (phosphate buffered saline (PBS), pH 7.4,
or glutamate buffer, pH 5) were sterilized by aseptic filtration.
Chitosan solutions (20 mg/mL) were prepared by dissolving
chitosan glutamate in water or glycol chitosan and ZWC in
PBS. ICR mice (25 g) (Harlan, Indianapolis, IN) were anesthetized
with subcutaneous injection of ketamine 50 mg/kg and xylazine
10 mg/kg. A 0.5 cm skin incision was made in the skin 0.5 cm
above the costal margin, and the peritoneum was nicked with a
24-gauge catheter. One milliliter of 20 mg/mL chitosan solutions
or control buffers were injected into the peritoneal cavity through
the catheter, and the skin was closed with suture. Animals were
sacrificed after 7 days to evaluate the presence of residues, tissue
adhesions, and visible signs of inflammation (nodules, increased
vascularization) in the peritoneal cavity. Liver and spleen were
sampled for histology, and the peritoneal fluid was sampled on a
slide for cytological analysis. After fixation in 10% formalin, the
sectioned organ samples and peritoneal fluid cells were stained
with hematoxylin and eosin (H&E).
Cell proliferation assay
Mouse peritoneal macrophages were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 5% fetal
bovine serum and 5 mM HEPES. Cells were seeded in 24 well
plates at a density of 50,000 cells per well in 1 mL culture medium.
After overnight incubation, chitosan solutions (2 or 20 mg/mL)
were added to make a final concentration of the medium 0.2 or
2 mg/mL. PBS and lipopolysaccharide (LPS) (1 mg/mL) were
added in control groups. MTT assay was performed after 24 hours
of incubation to determine the effects of chitosans on macrophage
proliferation.
Cytokine release from peritoneal macrophages
Peritoneal macrophages were seeded in 24-well plates at a
density of 150,000 cells per well in 1 mL of medium. After
overnight incubation, 100 mL of the chitosan solution was added
to each well to bring the final chitosan concentration in medium to
2 mg/mL. In control groups, 100 mL of PBS or glutamate buffer
(pH 5) was added in lieu of chitosan solutions. After 24 hour
incubation, the culture media were centrifuged at 2000 rpm for
10 min to separate supernatants. The concentrations of interleukin
(IL)-1b, IL-6, tumor necrosis factor (TNF)-a, and macrophage
inflammatory protein (MIP)-2 in the supernatant were determined
using a Milliplex Multi-Analyte Profiling (MAP) cytokine/
chemokine panel (Millipore, Billerica, MA). In another set of
experiments, macrophages were first challenged by adding LPS to
the media in the final concentration of 1 mg/mL shortly before the
chitosans or buffer controls. For selected samples, enzyme-linked
immunosorbent assay (ELISA) was performed to determine the
MIP-2 levels using an MIP-2 ELISA kit (R&D systems,
Minneapolis, MN). The detection range of MAP panel was 0–
10,000 pg/mL for all analytes. For MIP-2 ELISA, standard curves
were prepared in the range of 0–667 pg/mL. In both assays, the
supernatant collected from LPS-challenged macrophages was
always diluted 10 times prior to the analysis.
To investigate the time course of the ZWC effect on cytokine
production, ZWC or LMCS was added in the final concentration
of 2 mg/mL at 0, 2, 4, or 8 hours after the LPS addition. After
Zwitterionic Chitosan as a Functional Biomaterial
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incubating with chitosans for 24 hours, the culture media were
collected and diluted 10 times, and the MIP-2 levels were
determined using ELISA. For comparison, another set of
macrophages was challenged with LPS and incubated for 0, 2,
4, 8, or 24 hours, and the media were sampled without any
treatment or further incubation.
To investigate the effect of ZWC on LPS, LPS was
preincubated with ZWC before it was added to the cells. Briefly,
10 mg of LPS was mixed with 20 mg of ZWC in 1 mL of 0.9%
NaCl and incubated at room temperature for 1 hour. The ratio of
LPS to ZWC (10 mg per 20 mg) was consistent with the ratio used
in prior experiments (1 mg per 2 mg). ZWC was then precipitated
by decreasing the solution pH to 4.8 with 0.1–1 M HCl and
removed by 15-min centrifugation at 10,000 rpm. Assuming that
the LPS was present in the supernatant, a volume equivalent to
1 mg of LPS was sampled and added to 1 mL of peritoneal
macrophage culture. After overnight incubation, MIP-2 levels in
the culture media were determined using ELISA.
Endotoxin analysis
The amount of endotoxin present in each chitosan was
determined by the kinetic turbidometric Limulus Amebocyte
Lysate (LAL) assay at Associates of Cape Cod Inc. (East Falmouth,
MA). Chitosan samples were initially prepared as 1 mg/mL
(ZWC, LMCS) or 10 mg/mL (chitosan glutamate, glycol chitosan)
solutions in LAL reagent water (LRW) and then serially diluted
from 1:20 to 1:8000 to find the minimum concentration that did
not interfere with analysis. E. coli O113:H10 was used as a control
standard endotoxin and serially diluted from 0.32 to 0.002 EU/
mL to construct a calibration curve. Positive product controls were
prepared in parallel by fortifying the diluted samples with
additional endotoxin equivalent to 0.008 EU/mL. LRW was
tested as a negative control and found to contain less than the
lowest concentration of the calibration curve (0.002 EU/mL).
PyrotellH-T LAL lysate was reconstituted with Glucashield buffer,
a b-glucan inhibiting buffer, and mixed with samples or controls in
a 1:1 ratio in a depyrogenated microplate. The absorbance of each
well was monitored over time. The time required for the
absorbance to increase significantly over background was defined
as the onset time. The correlation coefficient for the regression of
log of onset time vs. log of endotoxin concentration was $0.98. All
samples were tested in duplicate. The results were reported as the
amount of endotoxin present in each chitosan (EU/g).
Statistical analysis
All data were expressed as mean 6 standard deviation. One-
way ANOVA was used to determine difference among the groups.
Multiple comparisons between treatments were performed with
Bonferroni’s test, and pair-wise comparison of each treatment with
the control group was performed with Dunnett’s test A value of
p,0.05 was considered statistically significant.
Results
Chitosan properties
All chitosans showed pH-dependence in aqueous solubilities
(data not shown) and corresponding charge profiles (Fig. 1).
Solutions of chitosan glutamate and LMCS (10 mg/mL) became
turbid at pH above 6.5 reaching the maximum turbidity at pH 8,
where they had neutral charges. On the other hand, ZWC
(10 mg/mL) formed clear solutions at both acidic and basic pHs,
indicating aqueous solubility, except at the pI value. The pI value
of ZWC decreased with the increase of the An/Am ratio (Fig. 1),
consistent with our previous report [22]. Glycol chitosan was
similar to chitosan glutamate and LMCS in that it showed neutral
charges around pH 8, but the solution (10 mg/mL) was not
turbid, which indicated the aqueous solubility of glycol chitosan.
Gross tissue responses to intraperitoneally administered
chitosans
ICR mice received IP injection of chitosan glutamate, glycol
chitosan, and ZWC (800 mg/kg). The animals were sacrificed
after 7 days, which was found to be an optimal time point for the
evaluation of inflammatory tissue responses [42]. During the
observation period, the animals did not show any signs of distress
and body weight change, similar to those treated with buffer
controls. Upon necropsy, the organs of animals treated with ZWC
or glycol chitosan were grossly normal. No material was found in
the peritoneal cavity of the mouse injected with glycol chitosan or
ZWC. On the other hand, white chitosan precipitates were seen in
all mice injected with chitosan glutamate due to the near-neutral
pH of the peritoneal fluid [43] (Fig. 2A). The white precipitates
were usually present on the liver and spleen (Fig. 2B). In 3 out of 4
cases, lobes of the liver were connected via the residual materials
(Fig. 2C).
Histological and cytological evaluation
Biomaterials delivered to peritoneal cavity often cause inflam-
matory responses followed by adhesion formation between in
peritoneal tissues and abdominal walls [44]. Once entering
systemic circulation, they can also cause abnormalities in filtering
organs [44]. To estimate the destination and effect of IP chitosan,
peritoneal fluid and organs as well as abdominal wall were
microscopically examined. Incidence of lesions in peritoneal tissues
is summarized in Table 1. In mice injected with PBS, glutamate
buffer, and ZWC, no significant microscopic differences were seen
in the liver (Fig. 3A, 3B, or 3C), spleen, and abdominal wall.
One mouse treated with glycol chitosan had mild inflammation of
the body wall, but liver (Fig. 3D) and spleen were normal.
Peritoneal tissues from other mice in this group were unremark-
able. In contrast, mice treated with chitosan glutamate had
noticeable chitosan precipitates on the liver, spleen and abdominal
wall, which were surrounded by macrophages and neutrophils
(Fig. 3E and 3F). Capsular surface of the liver adjacent to
Figure 1. pH-dependent zeta-potential profiles of unmodified
low molecular weight chitosan (LMCS) (data from the previous
study [22]) and zwitterionic chitosan (ZWC) derivatives pre-
pared with different anhydride to amine (An/Am) ratios,
chitosan glutamate (C-Gt), and glycol chitosan (Gly-C). Data
are expressed as averages with standard deviations of 3 repeated
measurements.
doi:10.1371/journal.pone.0030899.g001
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precipitates of chitosan was thickened and mildly fibrotic (Fig. 3E
and 3F). No abnormality was observed in peritoneal fluid of the
animals injected with PBS, glutamate buffer, or ZWC (Fig. 4A,
4B, and 4C). However, chitosan precipitates were detected in
peritoneal macrophages in mice treated with glycol chitosan
(Fig. 4D) or chitosan glutamate (Fig. 4E). Chitosan glutamate
was also observed as extracellular residues, surrounded by large
activated macrophages (Fig. 4E). No chitosan precipitates were
observed in those injected with ZWC (Fig. 4C).
Chitosan effect on macrophage proliferation
In an attempt to understand the difference in IP responses to
chitosan glutamate, glycol chitosan, and ZWC, in vitro prolifer-
ation of peritoneal macrophages was evaluated in the presence of
the three chitosans. Peritoneal macrophages were chosen because
they are prevalent in the peritoneal cavity and likely to be an
important player in inflammatory responses to IP injected
chitosans. For all chitosans, 0.2 mg/mL of chitosan treatment
did not negatively influence the macrophage proliferation (Fig. 5).
At 2 mg/mL, there was a moderate reduction in macrophage
proliferation with chitosan glutamate (p,0.01 vs. PBS). Gluta-
mate buffer (pH 5) added in an equivalent volume showed a
similar level of decrease in cell proliferation, indicating that this
reduction might be partly due to the acidity of the medium.
Neither glycol chitosan nor ZWC significantly reduced the
macrophage proliferation at 2 mg/mL.
Cytokine induction by chitosans
To investigate whether each chitosan had an intrinsic ability to
activate peritoneal macrophages, naı¨ve (non-challenged) peritone-
al macrophages were incubated with different chitosans (2 mg/
mL), and the medium was analyzed to determine the concentra-
tions of pro-inflammatory cytokines (IL-1b, TNF-a, IL-6 and
MIP-2). In this experiment, LMCS, the parent material for ZWC,
was also tested. Naı¨ve macrophages treated with PBS produced
3767 pg/mL of MIP-2, 6765 pg/mL of TNF-a, and 863 pg/
mL of IL-6, which were considered basal levels of cytokines. There
was no additional cytokine release in those treated with glutamate
buffer, glycol chitosan, LMCS, and ZWC. There was no
difference between LMCS and ZWC-treated groups. On the
other hand, chitosan glutamate treatment resulted in significant
increases in the levels of MIP-2 (p,0.001), TNF-a (p,0.05), and
IL-6 (p,0.01), as compared with PBS-treatment (Fig. 6A).
To investigate how each chitosan influenced the cytokine
production in activated macrophages, the cells were first
challenged with LPS, a potent inducer of cytokine release [45],
prior to the addition of chitosans (2 mg/mL). LPS-challenged,
then PBS-treated macrophages produced 23416564 pg/mL of
MIP-2, 106618 pg/mL of TNF-a, and 13466535 pg/mL of IL-
6 (Fig. 6B). Glutamate buffer caused increase in MIP-2
production, whereas chitosan glutamate did not have any
influence. LMCS treatment increased production of all three
cytokines from the LPS-challenged macrophages. Interestingly,
Figure 2. Chitosan precipitates (arrows) in the peritoneal cavity. Mice injected with chitosan glutamate intraperitoneally were examined 7
days after injection. (A) Chitosan precipitates found between the liver and the stomach. (B) Chitosan precipitates stuck on the spleen (top) and the
liver (bottom). (C) Lobes of the liver were connected via chitosan residue.
doi:10.1371/journal.pone.0030899.g002
Table 1. Incidence of lesions in tissues after intraperitoneal injection of chitosans and buffers.
PBS Glutamate buffer ZWC (An/Am=0.7) Glycol chitosan Chitosan glutamate
Liver, capsule inflammation 0/2a 0/3 0/5 0/4 4/4
Liver, capsular chitosan precipitates 0/2 0/3 0/5 0/4 4/4
Spleen, capsule inflammation 0/2 0/3 0/5 0/4 3/4
Spleen, capsular chitosan precipitates 0/2 0/3 0/5 0/4 3/4
Body wall, inflammation 0/2 0/3 0/5 1/4 3/4
Body wall, chitosan precipitates 0/2 0/3 0/5 0/4 0/4
Peritoneal fluid, inflammation 0/2 0/4 0/5 3/3 4/4
Peritoneal fluid, chitosan precipitates 0/2 0/4 0/5 3/3 4/4
aIncidence of occurrence: Number of mice with lesion/total number of mice examined.
doi:10.1371/journal.pone.0030899.t001
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ZWC caused a marked decrease in the LPS-induced production
of MIP-2 (p,0.01) and TNF-a (p,0.01) as compared with PBS.
Glycol chitosan also decreased the production of MIP-2 as
compared to PBS. Chitosan treatment did not cause any change
in IL-1b levels in either naı¨ve or LPS-challenged macrophages
(data not shown).
MIP-2 induction by chitosans with different number of
amine groups
The effects of chitosans on MIP-2 release from naı¨ve or LPS-
challenged macrophages were monitored varying the amine
content in the chitosan. We compared LMCS and ZWC with
different An/Am ratios (0.3 or 0.7), all at 2 mg/mL, with respect
to the ability to induce macrophages to produce MIP-2, the most
sensitive response in the prior experiment. From naı¨ve macro-
phages, LMCS induced a higher level of MIP-2 than PBS
(p,0.01), but no significant change was observed after ZWC
treatment (Fig. 7A). In LPS-challenged macrophages, LMCS
significantly increased the MIP-2 level (p,0.001). In contrast, the
two ZWC’s suppressed MIP-2 production from the LPS-
challenged macrophages (p,0.001 for An/Am: 0.7, p,0.05 for
An/Am 0.3 vs PBS) (Fig. 7B). ZWC (An/Am: 0.7) decreased the
Figure 4. Cytology of the peritoneal fluid from different treatment groups using hematoxylin and eosin staining. (A) PBS; (B)
Glutamate buffer; (C) ZWC. (A-C) Peritoneal fluid composed of small macrophages (box) and lymphocytes (arrows). No chitosan precipitates were
identified. (D) Glycol chitosan: peritoneal fluid is composed of large macrophages (box) containing chitosan. (E) Chitosan glutamate: peritoneal fluid
composed of large macrophages with intracellular eosinophilic chitosan. Extracellular chitosan (Ch) is surrounded by numerous macrophages. All
images are of 4006magnification.
doi:10.1371/journal.pone.0030899.g004
Figure 3. Hematoxylin and eosin staining of liver sections of different treatment groups. (A) PBS (100x); (B) Glutamate buffer (100x); (C)
ZWC (100x); (D) Glycol chitosan (100x). (A-D) Normal capsular surface (box). (E) Chitosan glutamate (100x): capsular surface of liver markedly
thickened with precipitates of chitosan, which are surrounded by chronic inflammation and mild fibrosis (box). (F) Chitosan glutamate (400x):
precipitates of chitosan on the liver surface surrounded by macrophages, fibroblasts, and neutrophils.
doi:10.1371/journal.pone.0030899.g003
Zwitterionic Chitosan as a Functional Biomaterial
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LPS-induced MIP-2 production to a greater extent than ZWC
(An/Am: 0.3).
Of note, MIP-2 levels measured by ELISA were not identical to
the values determined with the MAP panel, most likely due to the
difference between the two assay methods in the sensitive detection
ranges. However, results of the two assays were consistent in that
MIP-2 levels from LPS-challenged macrophages were at least two
orders of magnitude higher than those of naı¨ve macrophages and
that the MIP-2 production from the LPS-challenged macrophages
was significantly reduced by the ZWC treatment.
Onset of ZWC effect on LPS-induced MIP-2 production
To confirm the ability of ZWC to prevent LPS-induced
cytokine production and examine the onset of the action,
macrophages were first challenged with LPS for 0, 2, 4, or
8 hours. Subsequently, ZWC or LMCS were added to the
challenged macrophages, followed by additional 24 hour incuba-
tion. In ZWC-treated macrophages, the MIP-2 levels in the
culture media were comparable to those sampled prior to ZWC
treatment (Fig. 8). This result shows that cytokine production was
completely blocked from the time ZWC was added to the medium,
and proliferating cells did not further produce cytokines. In
contrast, LMCS-treated macrophages continued to produce MIP-
2, resulting in the same level as those grown for 24 hours without
any other treatment after LPS challenge.
LPS inactivation by ZWC
To investigate how ZWC prevented the MIP-2 production from
the LPS-challenged macrophages, LPS was incubated with ZWC
for 1 hour before it was given to the macrophages. ZWC was
removed by precipitation at pH 4.8 (,pI of ZWC) at the end of
the 1-h incubation so that the direct effect of ZWC on the cells
could be excluded. Fig. 9 shows that the LPS-induced MIP-2
production was reduced when ZWC coexisted in the culture,
consistent with prior experiments. The LPS pre-treated with ZWC
also lowered the MIP-2 production to a comparable level. This
result suggests that the reduction in MIP-2 production was due to
the inactivation of LPS by ZWC rather than a direct effect of
ZWC on the LPS-challenged cells. A similar trend was observed
with LPS pre-incubated at a higher ratio of LPS to ZWC (30 mg
LPS per 20 mg ZWC). Further increase of LPS (40 mg LPS per
20 mg ZWC) resulted in a significant production of MIP-2 (data
not shown), indicating that there was an upper limit of LPS that a
fixed amount of ZWC could inactivate.
Endotoxin content in chitosans
We hypothesized that ZWC inactivated LPS by high-affinity
interaction. To test this possibility, we determined the endotoxin
levels in all chitosans used in this study (Table 2). The levels were
comparable among chitosan glutamate, glycol chitosan, and
LMCS. However, endotoxin levels in ZWC were one or two
orders of magnitude higher than those of other chitosans. ZWC
with An/Am ratio 0.7 had highest endotoxin concentration. This
result suggests the relatively high affinity of ZWC to LPS.
Discussion
We previously reported that a new chitosan derivative ZWC
had excellent biocompatibility, comparing favorably with the
precursor chitosan (LMCS) in hemocompatibility and with
chitosan glutamate in the IP tissue responses [22]. Biological
activity of chitosan is often attributed to the positive charges
carried by the amine groups, which can electrostatically interact
with cell membranes or circulating plasma proteins and lead to
platelet adhesion/activation and thrombus formation [2,24,25].
Due to the ability to interact with serum proteins, chitosans
activate macrophages and induce cytokine production [2].
Chitosan derivatives with reduced positive charge densities
cause much lower platelet adhesion and aggregation than
original chitosan [46]. Aqueous solubility of chitosan in
physiological pH is also expected to play a role in biological
responses, because chitosan precipitates can be subjected to
phagocytic uptake and further stimulate macrophages. There-
fore, we hypothesized that the good hemocompatibility of ZWC
and the lack of pro-inflammatory effect might be related to the
reduced amine contents of ZWC and/or the aqueous solubility
at neutral pH.
To test this, we have first extended the evaluation of IP
biocompatibility to a greater variety of chitosans, which include
ZWC, glycol chitosan, and chitosan glutamate. ZWC and glycol
chitosan are water-soluble in physiological pH, whereas chitosan
glutamate precipitates at pH .6.5. Glycol chitosan and chitosan
glutamate are comparable in the degree of deacetylation (i.e.,
amine content), whereas ZWC has less amines due to partial
amidation with acid anhydride. The peritoneal cavity was used as
a location to test biocompatibility of these chitosans, because of its
well-known sensitivity to foreign insults, which results from the
peritoneal defense mechanisms [47,48]. We observed the most
inflammatory responses associated with chitosan glutamate,
although they were not as severe as in our previous experience
with a rabbit model [27]. The peritoneal fluid cytology of this
group showed eosinophilic chitosan debris surrounded by
macrophages. These results were consistent with a previous study,
where many macrophages with hyperplasia were observed in the
mesenterium after IP injection of chitosan [33]. The animals
treated with the water-soluble ZWC and glycol chitosan showed
relatively low incidence of tissue lesions. Considering the difference
in aqueous solubility of these chitosans, the inflammatory response
caused by chitosan glutamate is likely to be primarily due to its low
aqueous solubility in neutral pH, which results in precipitation of
chitosan in the peritoneal cavity. Macrophages react directly to the
Figure 5. Viability of mouse peritoneal macrophages in the
presence of ZWC (An/Am ratio=0.7), chitosan glutamate (C-Gt)
and glycol chitosan (Gly-C). Data are expressed as averages with
standard deviations of three repeated measurements. *: p,0.05;
**: p,0.01 vs PBS.
doi:10.1371/journal.pone.0030899.g005
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precipitated materials and elicit inflammatory reactions, ultimately
helping in degradation of the materials [49].
Chitosans have been shown to induce production of pro-
inflammatory cytokines or chemokines from macrophages
[27,29,31,33,50]. To examine if ZWC and glycol chitosan were
intrinsically less bioactive than other chitosans, we then
monitored the secretion of IL-1b, IL-6, TNF-a, and MIP-2
(murine functional homologue of IL-8 [51]) from peritoneal
macrophages after treating with different chitosans. These
cytokines or chemokines are responsible for both local and
systemic inflammatory responses [49] and have been used in
evaluating the safety of other chitosan based formulations
[27,30,31,49,52]. Production of MIP-2, IL-6, and TNF-a in
naı¨ve macrophages was increased by treatment with chitosan
glutamate but not with glycol chitosan, ZWC, or LMCS (Fig. 6A).
Chitosan glutamate is not particularly more cytotoxic than
others; therefore, the difference is unlikely due to the chemotactic
effect of dead cells. A potential explanation is the high molecular
weight of chitosan glutamate. Previous studies show that a
relatively high molecular weight chitosan induces higher cytokine
release from human keratinocytes [53]. Similarly, the relatively
high molecular weight of chitosan glutamate (200 kDa), as
compared to glycol chitosan (82 kDa), ZWC (15 kDa), and
LMCS (15 kDa), may account for the relatively high pro-
inflammatory effect of chitosan glutamate both in vivo and in
vitro. The effect of the primary amine content on the intrinsic pro-
inflammatory potential of chitosan is not readily apparent from
the MAP panel assay given the lack of difference between ZWC
and LMCS (Fig. 6A). ELISA detects a correlation between MIP-2
production and the amine content (LMCS.ZWC (An/
Am = 0.3).ZWC (An/Am = 0.7)), but the levels of MIP-2 are
close to the basal level in all cases (Fig. 7A). According to these
results, ZWC and glycol chitosan have relatively low potential to
cause inflammatory reactions in the peritoneal cavity by
themselves, and this property can be explained by their aqueous
solubility and relatively low molecular weights.
Figure 6. Effect of chitosan treatment (all in 2 mg/mL) on the levels of proinflammatory cytokines released from (A) naı¨ve mouse
peritoneal macrophages and (B) LPS-challenged macrophages. Cytokine levels are determined by Milliplex Multi-Analyte Profiling cytokine/
chemokine panel. Media of the LPS-challenged macrophages were 10 times diluted prior to analysis. Graphs on the right are displayed in narrow y-
scales. ZWC (An/Am=0.7); C-Gt: chitosan glutamate; Gly-C: glycol chitosan. Data are expressed as averages with standard deviations of three
repeated measurements. *: p,0.05; **: p,0.01; ***: p,0.001 vs PBS.
doi:10.1371/journal.pone.0030899.g006
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Additionally, we consider another scenario of parenteral
application, where chitosan is administered to tissues with lesions
that attract activated macrophages. Interestingly, only ZWC
suppressed the cytokine production from LPS-challenged macro-
phages significantly (Fig. 6B, Fig. 7B). Timed application of ZWC
revealed that MIP-2 production stopped as soon as ZWC was
applied (Fig. 8). There are at least two potential mechanisms by
which ZWC counteracts the LPS stimulation. First, ZWC may
bind the cell surface receptors and modify signaling pathways that
regulate cytokine production. Second, ZWC may tightly bind to
LPS and inactivate it. The fact that LPS pre-incubated with ZWC
lost the ability to induce MIP-2 (Fig. 9) supports the second
possibility. Moreover, ZWCs show much higher endotoxin content
than other chitosans, further supporting that ZWC has high
affinity to LPS. The mechanism of ZWC-LPS interaction is not yet
clear, but the ZWC–mediated inactivation of LPS appears to be
potent and irreversible, given that ZWC with such high endotoxin
content did not activate naı¨ve macrophages or induce inflamma-
tory responses in vivo. MIP-2 production from the LPS-challenged
macrophages decreased in the order of LMCS, ZWC (An/
Am = 0.3), and ZWC (An/Am = 0.7) (Fig. 7B), indicating that this
ability may be related to the amine content (inversely proportional
to the amidation degree, An/Am ratio) in chitosan.
While we find that the interaction of LPS with ZWC is
responsible for the reduced MIP-2 production from the LPS-
challenged macrophages, we do not rule out the possibility of
ZWC directly affecting the macrophages. Previous studies have
shown at the molecular level that chitosan oligosaccharides modify
the signaling mechanisms regulated by protein kinases and inhibit
LPS-induced cytokine production [38]. A similar effect was
observed with water-soluble chitosan or chitosan oligomers and
LPS-activated RAW macrophages [39,41].
The ability of ZWC to interact with LPS may be useful for a
variety of biomedical applications. Coming from the cell wall of
gram-negative bacteria, endotoxins are extremely potent stimula-
tors of mammalian immune system. Endotoxins are a common
cause of toxic reactions, and the level in parenteral products and
water is strictly limited by the regulatory authorities [54]. As a
scavenger of an endotoxin, ZWC may provide an efficient and
cost-effective way of removing endotoxicin from pharmaceutical
products.
In summary, ZWC showed excellent biocompatibility upon IP
administration and had no pro-inflammatory effect on naı¨ve
Figure 7. Effect of chitosan treatment (all in 2 mg/mL) on the
MIP-2 production from (A) naı¨ve mouse peritoneal macro-
phages and (B) LPS-challenged macrophages. MIP-2 level is
determined by ELISA. Media of the LPS-challenged macrophages were
10 times diluted prior to analysis. Data are expressed as averages with
standard deviations of three repeated measurements. **: p,0.01;
***: p,0.001.
doi:10.1371/journal.pone.0030899.g007
Figure 8. Effect of timed application of ZWC or LMCS (all in
2 mg/mL) on MIP-2 production in the LPS-challenged macro-
phages. Mouse peritoneal macrophages were incubated with LPS for
0, 2, 4, 8, or 24 hours, and the culture medium was sampled for
determination of the MIP-2 level (white bars). In another set,
macrophages were incubated with LPS for 0, 2, 4, or 8 hours with
LPS and then treated with ZWC or LMCS, and the media were sampled
after 24 hours (grey or black bars). Data are expressed as averages with
standard deviations of three repeated measurements.
doi:10.1371/journal.pone.0030899.g008
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macrophages. According to comparison with other chitosans,
these properties may be attributable to the aqueous solubility at
neutral pH and relatively low molecular weight of ZWC.
Moreover, ZWC had unique ability to suppress cytokine
production in LPS-challenged macrophages. The results suggest
that ZWC has a strong affinity to LPS and inactivates its pro-
inflammatory function. ZWC is a promising pharmaceutical
excipient for parenteral use and may be also useful as an
endotoxin scavenger.
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